10/04/2024
Congratulations Tania, from the team at Interaction! This is fantastic news for you and your team, as well as for the future of people living with PWS. We can't wait to see how the trial unfolds!
🌟 Congratulations to Tania and her team at RPAH! 🌟
We are delighted to announce that our 2023 PWRFA Grant of $50,000 is awarded to A/Prof Tania Markovic and her team at the Royal Prince Alfred Hospital (RPAH), to investigate the safety of tirzepatide in individuals with PWS.
Tirzepatide is marketed by Eli Lilly as Mounjaro for diabetes, and Zepbound for obesity. It targets specific receptors in the body (GIP and GLP-1), aiding in blood sugar regulation and appetite reduction, which can lead to enhanced insulin sensitivity and weight loss.
However, individuals with PWS often encounter gastrointestinal difficulties, including severe constipation and the risk of stomach rupture. As tirzepatide influences stomach emptying, it is crucial to determine its safety for use in people with PWS.
With the support of the grant from PWRFA, A/Prof Markovic and her team will:
Gain Insight: understand gastric emptying and intestinal transit before and after tirzepatide treatment, exploring potential treatment avenues.
Ensure Safety: Monitor participants to assess tirzepatide's safety and any changes in bowel function, vital for individuals with PWS.
Explore Benefits: Investigate effects on weight, appetite, behaviour, and metabolism in individuals with PWS, building pilot data for future research.
Stay tuned to our page for updates on recruitment for this clinical trial. Join us in our mission to change lives.
Thank you to all of our donors. These are your funds at work to change life for our loved ones with PWS.